1. Scrip
  2. >>Therapy Areas

Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS Pathways Hopes To Market its Psilocybin Capsule By 2025

 
• By Sten Stovall

COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.

Mushrooms_Brain
UK-Based group’s psilocybin therapy has fast track status • Source: Shutterstock

COMPASS Pathways believes it has found a viable, mind-altering therapy for treating long-term depression: a synthetic form of psilocybin now in Phase IIb trials which, if successful, could surmount current legal barriers and stigma associated with psychedelic substances, the company’s co-founder and chief innovation officer told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.